The advent of tyrosine kinase inhibitors (TKIs) revolutionized the treatment landscape for CML, dramatically improving patient survival to the extent that it is now comparable to that of the general population. Despite this remarkable progress, the long-term administration of TKIs poses challenges such as side effects, toxicity, and high costs. As a result, discontinuing TKI therapy has become an important goal for patients with chronic phase CML.
A subset of patients who meet the stringent criteria for DMR and discontinue TKI therapy can remain in treatment-free remission (TFR) without disease progression. However, relapses can occur, predominantly within the first six months following TKI discontinuation.
In this Research Topic, we welcome authors to submit papers focused on the biological and therapeutic advances in CML including, but not limited to:
- Possible prognostic factors of relapse after discontinuation
- Cardiovascular side effects and TKI toxicity.
- Innovative strategies targeting leukemic stem cells or methods to inhibit signal pathways or favor immune responses, to improve and better understand the TFR.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
The advent of tyrosine kinase inhibitors (TKIs) revolutionized the treatment landscape for CML, dramatically improving patient survival to the extent that it is now comparable to that of the general population. Despite this remarkable progress, the long-term administration of TKIs poses challenges such as side effects, toxicity, and high costs. As a result, discontinuing TKI therapy has become an important goal for patients with chronic phase CML.
A subset of patients who meet the stringent criteria for DMR and discontinue TKI therapy can remain in treatment-free remission (TFR) without disease progression. However, relapses can occur, predominantly within the first six months following TKI discontinuation.
In this Research Topic, we welcome authors to submit papers focused on the biological and therapeutic advances in CML including, but not limited to:
- Possible prognostic factors of relapse after discontinuation
- Cardiovascular side effects and TKI toxicity.
- Innovative strategies targeting leukemic stem cells or methods to inhibit signal pathways or favor immune responses, to improve and better understand the TFR.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
